Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
- Published in:
- 2009
- By:
- Publication type:
- journal article
Works matching IS 14741776 AND DT 2009 AND VI 8 AND IP 7
Results: 25
1
2
The 'big pharma' dilemma: develop new drugs or promote existing ones?
- Published in:
- 2009
- By:
- Publication type:
- journal article
3
Assessing the translatability of drug projects: what needs to be scored to predict success?
- Published in:
- 2009
- By:
- Publication type:
- review
4
Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds.
- Published in:
- 2009
- By:
- Publication type:
- journal article
5
Cell cycle kinases as therapeutic targets for cancer.
- Published in:
- 2009
- By:
- Publication type:
- journal article
6
Everolimus.
- Published in:
- 2009
- By:
- Publication type:
- journal article
7
Translational medicine.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 593, doi. 10.1038/nrd2925
- By:
- Publication type:
- Article
8
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 530, doi. 10.1038/nrd2928
- By:
- Publication type:
- Article
9
Peter Kiener.
- Published in:
- 2009
- Publication type:
- Interview
10
Anti-obesity drugs: Improving sleep may promote weight loss.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 538, doi. 10.1038/nrd2930
- By:
- Publication type:
- Article
11
Mood disorders: Channel inhibitor shows antidepressant potential.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 540, doi. 10.1038/nrd2931
- By:
- Publication type:
- Article
12
Inflammatory diseases: Targeting prostanoid receptors.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 537, doi. 10.1038/nrd2932
- By:
- Publication type:
- Article
13
Anticancer drugs: Prioritizing targets.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 539, doi. 10.1038/nrd2933
- By:
- Publication type:
- Article
14
Neurodegenerative disorders: HDAC2 is the one.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 538, doi. 10.1038/nrd2934
- By:
- Publication type:
- Article
15
In Brief.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 540, doi. 10.1038/nrd2935
- Publication type:
- Article
16
Deal watch: Amgen licenses Cytokinetics' heart failure agent.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 528, doi. 10.1038/nrd2936
- Publication type:
- Article
17
Deal watch: J&J buys biotech with promising prostate cancer therapy.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 528, doi. 10.1038/nrd2937
- Publication type:
- Article
18
Trial watch: Novel obesity therapies set to attract spotlight in Q3 2009.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 529, doi. 10.1038/nrd2938
- By:
- Publication type:
- Article
19
End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.
- Published in:
- 2009
- By:
- Publication type:
- Letter
20
Novel consortium to address shortfall in innovative medicines for psychiatric disorders.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 523, doi. 10.1038/nrd2939
- By:
- Publication type:
- Article
21
Teaming up to tackle RNAi delivery challenge.
- Published in:
- 2009
- By:
- Publication type:
- journal article
22
In this issue.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 519, doi. 10.1038/nrd2942
- Publication type:
- Article
23
A mixed record.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 521, doi. 10.1038/nrd2943
- Publication type:
- Article
24
Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin.
- Published in:
- 2009
- By:
- Publication type:
- commentary
25
News in Brief.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 7, p. 527, doi. 10.1038/nrd2941
- Publication type:
- Article